Table 3 Baseline characteristics of enrolled participants for each trial included in meta-analysis: II

Martineau 2011 [21]

30.7 (24.5–41.5) /30.5 (24.8–38.4)^b

98/28

146/126, at 0, 2, 4 & 6 weeks

5/93 (5.4)

1/135 (0.7)

Daley 2015 [16]

41·6 ± 15·1/ 43·7 ± 14·3″

189/58

247/211, at 0, 2, 4, & 6 weeks

0/209 (0)

1/209 (0.5)

Farazi 2017 [36]

52.4 ± 17.6/ 51.8 ± 18.2″

31/29

68/60 at week 0 only

0/60 (0)

ND

Mily 2015 [18]

27.2 ± 8.0 / 26.7 ± 8.1″

177/111

288/260 daily for 8 weeks

ND

7/260 (2.7)

Nursyam 2006 [37]

29.85 ± 11.08 / 32.55 ± 11.6″

39/28

67/67 daily for 6 weeks

0/67 (0)

ND

Ralph 2013 [20]

29 (15–65)/ 26 (15–73) ^b

131/69

200/164 at 0 & 4 weeks

19/123 (15.4)

2/164 (1.2)

Salahuddin 2013 [14]

27.8 ± 13.2 / 28.3 ± 14.1″

141/118

259/259 at 0 & 4 weeks

ND

ND

Tukvadze 2015 [39]

32.4 6 ± 10.6 / 34.1 6 ± 12.4″

127/72

199/192 weekly for 8 weeks,then fortnightly for 8 weeks

3/184 (1.6)

23/192 (12.0)

Wejse 2009 [38]

37 ± 13/ 38 ± 14”

222/145

367/241 at 0,20 & 32 weeks

82/240 (34.2)

ND

Johnson 2003 [40]

26.7 ± 7 / 27.4 ± 7″

75/35

110/110 daily for 4 ^1/2 weeks

0/110 (0)

2/110 (1.8)

Mayanja-Kizza 2005 [41]

31.0 ± 7.1/ 31 ± 7.2″

113/74

187/187 daily for 8 weeks

187/187 (100)

ND

Pedral-Sampaio 2003 [44]

31.6 ± 10.9/ 28.0 ± 6.2″

16/15

31/31twice weekly for 4 weeks

0/31 (0)

ND

Willis 1996 [42]

28.1 ± 0.7 / 29.9 ± 1.0″

NM

107/107 daily for 16 weeks

107/107 (100)

ND

Mahakalkar 2017 [43]

31.96 ± 13.14 / 29.79 ± 11.12″

27/21

62/48 daily for 8 week

ND

NM

Ganmaa 2017 [15]

31 (23–44) / 35 (25–47) ^b

256/134

390/390 at 0, 2, 4 & 6 weeks

ND

21/390 (5.4)